High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.
Saved in:
| Title: | High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. |
|---|---|
| Authors: | Gülave B; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands., Hew MN; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. Electronic address: mn.hew@cbg-meb.nl., de Groot JS; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands., Rodwell L; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Teerenstra S; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Fabriek BO; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. |
| Source: | ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100107. Date of Electronic Publication: 2021 Apr 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
